David Asboe

Summary

Affiliation: Chelsea and Westminster Hospital
Country: UK

Publications

  1. ncbi request reprint Sexual dysfunction in HIV-positive men is multi-factorial: a study of prevalence and associated factors
    D Asboe
    Directorate of HIV GU Medicine, Chelsea and Westminster Hospital, London, UK
    AIDS Care 19:955-65. 2007
  2. doi request reprint British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011
    D Asboe
    British HIV Association BHIVA, BHIVA Secretariat, Mediscript Ltd, London, UK
    HIV Med 13:1-44. 2012
  3. ncbi request reprint Enfuvirtide: antiretroviral class 4, drug 1
    David Asboe
    Chelsea and Westminster Hospital, London, UK
    HIV Clin Trials 5:1-6. 2004
  4. ncbi request reprint Sequencing to NRTI plus NNRTI-only combinations after virological failure of protease inhibitor-based combination HIV-1 therapy
    D Asboe
    Genitourinary Medicine, St Stephen s Centre, Chelsea and Westminster Hospital, London, United Kingdom
    HIV Clin Trials 4:1-10. 2003
  5. ncbi request reprint Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone
    Laura Waters
    Department of GU HIV Medicine, Mortimer Market Centre, London, UK
    Antivir Ther 18:213-9. 2013
  6. doi request reprint Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data
    Huw Price
    Chelsea and Westminster NHS Foundation Trust, London, UK
    Antivir Ther 15:203-11. 2010
  7. doi request reprint Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor
    Tristan J Barber
    Medical Research Council Clinical Trials Unit, St Stephen s Centre, Chelsea and Westminster Hospital, 125 Kingsway, London, UK
    J Antimicrob Chemother 67:995-1000. 2012
  8. ncbi request reprint A virological benefit from an induction/maintenance strategy: the Forte trial
    David Asboe
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 12:47-54. 2007
  9. doi request reprint The effect of transmitted HIV-1 drug resistance on pre-therapy viral load
    Linda Harrison
    HIV and Infections Group, MRC Clinical Trials Unit, London, UK
    AIDS 24:1917-22. 2010
  10. doi request reprint Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK
    Julie Fox
    Department of HIV, Guys and St Thomas NHS Trust Kings College London, St Thomas Hospital, London, UK
    AIDS 24:2397-401. 2010

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Sexual dysfunction in HIV-positive men is multi-factorial: a study of prevalence and associated factors
    D Asboe
    Directorate of HIV GU Medicine, Chelsea and Westminster Hospital, London, UK
    AIDS Care 19:955-65. 2007
    ..No significant association was seen with specific classes of anti-retrovirals. Older age, and depression were the variables most consistently associated with both EDF and LSD...
  2. doi request reprint British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011
    D Asboe
    British HIV Association BHIVA, BHIVA Secretariat, Mediscript Ltd, London, UK
    HIV Med 13:1-44. 2012
  3. ncbi request reprint Enfuvirtide: antiretroviral class 4, drug 1
    David Asboe
    Chelsea and Westminster Hospital, London, UK
    HIV Clin Trials 5:1-6. 2004
    ..In this article, enfuvirtide is discussed with particular emphasis on the clinical trials that led to the drug's licensing. The possible placement of enfuvirtide in the sequence of treatment is also discussed...
  4. ncbi request reprint Sequencing to NRTI plus NNRTI-only combinations after virological failure of protease inhibitor-based combination HIV-1 therapy
    D Asboe
    Genitourinary Medicine, St Stephen s Centre, Chelsea and Westminster Hospital, London, United Kingdom
    HIV Clin Trials 4:1-10. 2003
    ....
  5. ncbi request reprint Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone
    Laura Waters
    Department of GU HIV Medicine, Mortimer Market Centre, London, UK
    Antivir Ther 18:213-9. 2013
    ..We investigated the effect of an NRTI backbone in individuals receiving Pl/r after failing NNRTI-based combined antiretroviral therapy...
  6. doi request reprint Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data
    Huw Price
    Chelsea and Westminster NHS Foundation Trust, London, UK
    Antivir Ther 15:203-11. 2010
    ..Here, we examined associations between the emergence of N348I and antiretroviral history in a large clinical database...
  7. doi request reprint Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor
    Tristan J Barber
    Medical Research Council Clinical Trials Unit, St Stephen s Centre, Chelsea and Westminster Hospital, 125 Kingsway, London, UK
    J Antimicrob Chemother 67:995-1000. 2012
    ..Scarce data exist from long-term cohorts on resistance incidence or mutational patterns emerging to different PIs...
  8. ncbi request reprint A virological benefit from an induction/maintenance strategy: the Forte trial
    David Asboe
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 12:47-54. 2007
    ..To evaluate whether the addition of a fourth drug for up to 32 weeks to a standard three-drug antiretroviral combination decreases the risk of virological failure without increasing toxicity in treatment-naive patients...
  9. doi request reprint The effect of transmitted HIV-1 drug resistance on pre-therapy viral load
    Linda Harrison
    HIV and Infections Group, MRC Clinical Trials Unit, London, UK
    AIDS 24:1917-22. 2010
    ..Reduced replication capacity of viruses expressing drug resistant mutations implies that patients with transmitted drug resistance (TDR) could have lower HIV RNA viral load than those infected with wild-type virus...
  10. doi request reprint Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK
    Julie Fox
    Department of HIV, Guys and St Thomas NHS Trust Kings College London, St Thomas Hospital, London, UK
    AIDS 24:2397-401. 2010
    ..To describe the frequency and risk factors of non-B HIV-1 subtypes in men who have sex with men (MSM) in the UK...
  11. pmc Persistence of HIV-1 transmitted drug resistance mutations
    Hannah Castro
    Medical Research Council Clinical Trials Unit, London, United Kingdom
    J Infect Dis 208:1459-63. 2013
    ..Our estimates are important for informing HIV transmission models. ..
  12. doi request reprint Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone
    Laura Waters
    Department of GU HIV Medicine, Mortimer Market Centre, London, UK
    Antivir Ther 18:213-9. 2013
    ..We investigated the effect of an NRTI backbone in individuals receiving PI/r after failing NNRTI-based combined antiretroviral therapy...
  13. doi request reprint HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom
    Daniella N Chilton
    Medical Research Council Clinical Trials Unit, London, UK
    Antivir Ther 15:985-91. 2010
    ..We examined the characteristics of HIV-1 drug resistance in antiretroviral treatment (ART)-naive individuals migrating to the UK...
  14. doi request reprint The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom
    Hannah Green
    HIV Group, Medical Research Council Clinical Trials Unit, 222 Euston Road, London, United Kingdom
    J Acquir Immune Defic Syndr 49:196-204. 2008
    ..The use of different lists of resistance mutations has resulted in estimates of transmitted HIV drug resistance (THDR) that are often not comparable...
  15. ncbi request reprint Successful use of genotypic resistance testing in HIV-1-infected individuals with detectable viraemia between 50 and 1000 copies/ml
    Laura Waters
    Department of Genitourinary and HIV Medicine, St Stephens Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 20:778-9. 2006
    ..Amplification was significantly more likely for 200-1000 copies/ml than 50-200 copies/ml; most samples amplified successfully, supporting the use of genotyping for low-level viraemia...
  16. doi request reprint Unselected hepatitis C screening of men who have sex with men attending sexual health clinics
    Christopher Scott
    St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom
    J Infect 60:351-3. 2010
    ..65% (95% CI 0.36-1.1). This is similar to the prevalence of HCV in the general population within England. We conclude that unselected screening of MSM for HCV within our sexual health services is not currently justified...
  17. doi request reprint Reduced T(H)1/T(H)17 CD4 T-cell numbers are associated with impaired purified protein derivative-specific cytokine responses in patients with HIV-1 infection
    Sally Clark
    Immunology Section, Division of Infectious Diseases, Imperial College, Chelsea and Westminster Hospital Campus, London, UK
    J Allergy Clin Immunol 128:838-846.e5. 2011
    ..Selective loss of T(H)1/T(H)17 cells in patients with HIV-1 infection might contribute to reduced tuberculosis-induced immune responses and an increased susceptibility to active tuberculosis...
  18. ncbi request reprint Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors
    Graeme J Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS 16:1341-9. 2002
    ..To evaluate the prevalence, outcome and possible risk factors for hyperlactataemia and lactic acidosis in HIV-positive persons receiving antiretroviral therapy...
  19. ncbi request reprint The International Index of Erectile Function: development of an adapted tool for use in HIV-positive men who have sex with men
    Katherine Coyne
    Chelsea and Westminster Hospital, HIV GUM Directorate, St Stephen s Centre, London, UK
    J Sex Med 7:769-74. 2010
    ..Erectile dysfunction is common in HIV-positive men who have sex with men (MSM). A standardized scale is needed to assess erectile function in clinical practice and research studies...
  20. doi request reprint Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers
    Marta Boffito
    Department of HIV GUM Medicine, St Stephen s Centre, Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 52:222-7. 2009
    ..To assess the pharmacokinetics of etravirine once and twice daily without and with a preceding efavirenz intake period in healthy volunteers...
  21. ncbi request reprint Acne vulgaris and acne rosacea as part of immune reconstitution disease in HIV-1 infected patients starting antiretroviral therapy
    Christopher Scott
    Chelsea and Westminster Hospital, London, UK
    Int J STD AIDS 19:493-5. 2008
    ..This serves as a reminder not to overlook dermatological manifestations of disease in patients with HIV infection after starting antiretrovirals...
  22. ncbi request reprint Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin
    Yvonne C Gilleece
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 40:41-6. 2005
    ..To evaluate treatment outcome of acute hepatitis C virus (HCV) in HIV-positive individuals...
  23. ncbi request reprint Pharmacology lessons from chemoprophylaxis studies
    Marta Boffito
    St Stephen s Centre, Chelsea and Westminster Hospital, London, United Kingdom
    Clin Infect Dis 59:S52-4. 2014
    ..Notably, clinical pharmacology studies play a central role in interpreting drug concentration-responses and optimal drug exposure achievement. ..
  24. pmc Simvastatin co-prescribed with protease inhibitors despite dangerous drug interactions
    Katherine M Coyne
    Sex Transm Infect 83:498. 2007